Men and women manage energy and protect nerve connections differently
For decades, the greater burden Parkinson's disease places on men has been a medical fact without a cellular explanation. Now, researchers at Saarland University have peered into post-mortem brain tissue and found that while the disease speaks a common language of stress to all brain cells, it speaks differently to men and women in the cells that manage energy and protect nerve fibers. This discovery — presented at a major European neuroscience forum in July 2026 — does not merely satisfy scientific curiosity; it opens a path toward medicine that treats patients as the biologically distinct individuals they are.
- Men develop Parkinson's disease up to twice as often as women and lose cognitive function faster, yet the biological reasons have remained stubbornly opaque — until now.
- Examining brain tissue from 73 patients across five brain regions, researchers found that support cells called astrocytes and oligodendrocytes behave differently in men and women, diverging in how they handle energy and protect nerve fibers.
- A shared cellular stress response — the brain marshaling chaperone proteins to manage damaged cells — runs through all patients regardless of sex, but this common signal has been masking the sex-specific differences hiding beneath it.
- Earlier blood-sample research found women with early Parkinson's showed DNA methylation changes in 69 genomic regions versus only two in men, suggesting the divergence begins long before symptoms are visible.
- The findings are pushing toward a concrete shift: sex-specific clinical predictions, earlier symptom monitoring, and personalized treatments — with Germany's Research Foundation launching a dedicated program called 'SEX and GLIA' in autumn 2026 to accelerate the work.
Parkinson's disease has long been known to strike men roughly one and a half to twice as often as women, and to erode their cognitive function more quickly — yet the cellular machinery behind this disparity remained largely invisible. Affecting 9.4 million people worldwide, the disease has mostly been studied without separating male and female biology, a gap that a team led by Dr. Julia Schulze-Hentrich at Saarland University set out to close.
Presenting findings at the Federation of European Neuroscience Societies Forum this week, the researchers analyzed post-mortem brain tissue from 73 people with Parkinson's and 24 healthy controls, examining not only neurons but the brain's support cells — astrocytes, oligodendrocytes, and microglia — across five brain regions. What emerged was a story of both shared suffering and biological divergence. All cell types showed a common stress response, activating chaperone proteins to help manage damaged cellular machinery. But astrocytes, which govern energy production, and oligodendrocytes, which maintain the protective myelin sheath around nerve fibers, showed distinctly different gene activity patterns between men and women — consistently, across every brain region studied.
This cellular-level divergence helps explain why the disease progresses differently between sexes. It also connects to earlier findings from the same team, who studied blood samples from agricultural workers and found that women with early Parkinson's exhibited DNA methylation changes — a kind of molecular dimmer switch on gene activity — in 69 genomic regions, compared to just two in men. Environmental exposures such as pesticides may amplify these differences.
The practical stakes are significant. Understanding that Parkinson's manifests differently in men and women at the cellular level could allow clinicians to predict symptoms more accurately, intervene earlier, and move away from one-size-fits-all treatment. Schulze-Hentrich has been direct: pooling male and female data together in research obscures real effects, and many studies still do exactly that. The sample size here is modest, and larger coordinated studies are needed — a need the German Research Foundation is beginning to answer with its 'SEX and GLIA' Priority Programme launching in autumn 2026. The deeper question is whether this science will actually change clinical practice, transforming cellular insight into more precise, more human care.
Parkinson's disease hits men harder than women—roughly one and a half to twice as hard—and for decades, nobody quite understood why. The condition damages the brain progressively over years, affecting some 9.4 million people worldwide. Men not only get it more often; they also decline faster, losing cognitive sharpness and the ability to manage daily life at a steeper rate. Yet the biological machinery behind this sex difference remained largely invisible.
A team led by Dr. Julia Schulze-Hentrich at Saarland University in Germany presented new findings this week at the Federation of European Neuroscience Societies Forum that begin to illuminate what's happening inside the brain cells of men and women with Parkinson's. The researchers examined post-mortem brain tissue from 73 people with the disease (28 women and 45 men) and compared it to samples from 24 healthy controls (9 women and 15 men). They looked not just at neurons—the brain's communication cells—but also at the support cells: astrocytes, oligodendrocytes, and microglia, which maintain the brain's infrastructure.
What they found was a picture of both unity and divergence. Across all cell types and all five brain regions studied, Parkinson's triggered a shared stress response. Cells switched on proteins called chaperones, which help damaged proteins fold correctly—a sign that the brain is struggling under the weight of the disease. But layered over this common response were sex-specific differences. In astrocytes, the cells that manage energy production, genes linked to mitochondria showed different activity levels between men and women. In oligodendrocytes, the cells responsible for maintaining myelin—the protective coating around nerve fibers—gene activity also diverged by sex. These differences appeared regardless of which brain region was examined.
Schulze-Hentrich explained the significance: Parkinson's triggers shared stress responses in everyone's brain cells, but men and women manage energy and protect nerve connections differently at the cellular level. This cellular-level divergence helps explain why symptoms and disease progression vary between sexes. The findings emerged from earlier work in which the team studied blood samples from agricultural workers, finding that women with early Parkinson's showed DNA methylation changes in 69 regions of the genome, while men showed changes in only two. DNA methylation acts like a dimmer switch on gene activity, turning it up or down without altering the genes themselves. That earlier research suggested that genetic makeup influences these methylation patterns, and that environmental exposures—such as pesticides—may also play a role.
The implications for patients are concrete. If clinicians understand that Parkinson's manifests differently in men and women at the cellular level, they can make better predictions about which symptoms are likely to emerge, catch problems earlier, and choose treatments tailored to a patient's individual risk profile. Instead of treating all Parkinson's patients as biologically identical, medicine could become more personalized. Schulze-Hentrich emphasized that researchers need to stop pooling male and female data together in their analyses. When studies combine the sexes, they often miss associations and effects that only show up when the data is separated. Many studies still under-report or obscure sex-specific outcomes entirely.
The study has limitations. The sample size is small—73 people with disease and 24 controls—and a coordinated, larger effort is needed to confirm and extend these findings. But the strength lies in examining multiple cell types across multiple brain regions, filling a gap left by earlier research that focused narrowly on neurons and male subjects. To build on this work, the German Research Foundation is launching a Priority Programme called "SEX and GLIA" in autumn 2026, bringing together physiologists, functional geneticists, and computational biologists to systematically uncover the sex-biased biology that previous studies have largely ignored. The question now is whether this cellular-level understanding can translate into clinical practice—whether doctors will actually use sex-specific insights to change how they diagnose, monitor, and treat Parkinson's disease.
Citações Notáveis
Sex-dependent biology may influence vulnerability to Parkinson's disease, and studying sex differences may help identify disease mechanisms that would be hidden if men and women are analyzed together.— Dr. Julia Schulze-Hentrich, Saarland University
Researchers should analyze data separately in males and females instead of pooling everyone together, as this is crucial to see whether an association, effect or outcome differs by sex.— Dr. Julia Schulze-Hentrich
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that men and women show different gene activity in support cells rather than just in neurons?
Because support cells are the brain's infrastructure. If astrocytes manage energy differently in men versus women, that shapes how well the brain can cope with Parkinson's damage. You can't understand disease progression without understanding the whole system.
The study looked at post-mortem brains. Can you actually use that to predict what happens in living patients?
It's a starting point. You're seeing the end state of the disease in the tissue itself. The next step is to find biomarkers in living people—in blood or cerebrospinal fluid—that reflect these same cellular differences. Then you can intervene earlier.
If women show more DNA methylation changes but get Parkinson's less often, doesn't that seem backwards?
Not really. It suggests women's brains might be compensating differently, or that the methylation changes are a response to environmental stress rather than a cause of disease. The genetics and environment interact. Men might be more vulnerable to that interaction.
What would personalized treatment actually look like?
Right now, everyone gets dopamine-boosting drugs. But if you know a woman's astrocytes are struggling with energy management, you might add mitochondrial support. If a man's myelin is degrading faster, you target that. Same disease, different cellular problems, different solutions.
Why haven't researchers been doing this sex-specific analysis all along?
Partly inertia. Partly because studies were smaller and pooling data seemed more statistically robust. But mostly because the field didn't prioritize it. You don't see what you're not looking for.